Drug delivery systems for treating Diseases of the Anterior Segment of the Eye

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo0 个研究点开始时间: 2023年10月16日最近更新: 2023年11月13日

试验速览

暂无简介。

•The authors intend to include 60 participants, divided into three groups of 20 (Experimental Group I: insulin eye drops; Experimental Group II: cannabidiol eye drops; Placebo Group: eye drops without active ingredient). Subjects must meet all inclusion criteria to be eligible to participate in the study: subjects of any color and gender, over 18 years of age at the time of enrollment; read, understand, and sign the informed consent form; understand the study procedures and adhere to them throughout the study; have a history of dry eye, and have used tear-lubricating agents within the last 4 months; basal tear <5 mm; Corneal coloration 2 (NEI grading system, Lemp 1995) in at least one eye

•Subjects who meet any of the exclusion criteria at visit 1 will be excluded from participation in the study: subjects who have any active infectious ocular conditions; individuals with inflammatory eye diseases (eg, conjunctivitis, keratitis, uveitis, or others) unrelated to dry eye; continued use of topical eye medications (including ocular cyclosporine and glaucoma medications) with the exception of artificial tears or lubricating ointments; taking medications that can cause dry eyes immediately prior to this study (Wong, Lan et al. 2011); any physical or mental disability that impedes participation and the ability to give informed consent

发起方

Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo